Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates
Portfolio Pulse from
Tango Therapeutics, Inc. (TNGX) reported a Q4 loss of $0.35 per share, missing the Zacks Consensus Estimate of a $0.32 loss. This is a larger loss compared to the $0.32 per share loss from the previous year.
February 27, 2025 | 2:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Tango Therapeutics reported a larger-than-expected Q4 loss of $0.35 per share, missing the consensus estimate of $0.32. This indicates a worsening financial performance compared to the previous year.
The reported loss per share of $0.35 is worse than both the consensus estimate and the previous year's loss, suggesting negative sentiment and potential downward pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100